Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Eating Disorders

LSD for Eating Disorders

4 papers and 0 clinical trials exploring lsd as a treatment for eating disorders.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
Indication16 million people worldwide.

Eating Disorders

Eating disorders, including anorexia nervosa and bulimia nervosa, affect approximately 16 million individuals globally. The exploration of psychedelics, such as psilocybin and MDMA, as potential treatments for these conditions is a burgeoning field of research, showing promise in alleviating symptoms and improving quality of life.

Full Eating Disorders profile

Academic Research

4 papers
Paywallmeta

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

This mini‑review argues that 5‑HT2A activation is only one facet of serotonergic psychedelic action, which also involves other serotonin receptors (5‑HT1A, 5‑HT2C), neurotrophin receptors (e.g. TrkB), promotion of neuroplasticity and possible protein post‑translational modifications. It highlights efforts to develop non‑hallucinogenic derivatives that retain therapeutic neuroplastic effects while minimising the intense psychedelic experience.

Published
November 8, 2023
Journal
Journal of Neuroscience
Authors
Cameron, L. P., Benetatos, J., Lewis, V., Bonniwell, E. M., Jaster, A. M., Moliner, R., Castrén, E., Mccorvy, J. D., Palner, M., Aguilar-Valles, A.
Open Accessmeta

Neuroimaging in psychedelic drug development: Past, present, and future

This review (2023) discusses the emerging field of psychedelic therapy for psychiatric disorders, emphasizing the potential of classic serotonergic psychedelics like psilocybin and LSD and substances like ketamine, MDMA, and ibogaine. It highlights the role of advanced neuroscientific research methods, particularly neuroimaging using Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), in advancing the understanding of drug and therapy effects on the brain. The article identifies key knowledge gaps, including the relationship between acute and longer-term effects, the precise characterization of effects at the 5-HT2A receptor, and the impact of these compounds on neuroplasticity, and proposes a roadmap for future research to address these questions through multimodal PET/MRI studies.

Published
September 27, 2023
Journal
Molecular Psychiatry
Authors
Wall, M. B., Harding, R., Zafar, R., Rabiner, E. A., Nutt, D. J., Erritzoe, D.
Paywallindividual

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults

This double-blind study (n=22) investigated the effects of microdosing LSD (13μg & 26μg) on resting-state electroencephalography (EEG) and event-related potential (ERP) in healthy adults. The study found that microdoses of LSD produced desynchronization patterns similar to those reported with higher doses of psychedelics, leading the authors to believe that microdoses of LSD may produce therapeutic effects in the absence of a full psychedelic experience.

Published
October 6, 2021
Journal
Psychopharmacology
Authors
Perry, C. M., Malina, M.
Open Accessmeta

Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.

This review (s=8) found that psychedelics (LSD, psilocybin) can aid in the recognition of emotions in facial expressions (REFE), which is thought to be a key aspect of social cognition. Psychedelics do this by modulating the activity of the amygdala.

Published
April 23, 2019
Journal
Therapeutic Advances in Psychopharmacology
Authors
Rocha, J. M., Osório, F. L., Crippa, J. A., Bouso, J. C., Rossi, G. N., Hallak, J. E., Dos Santos, R. G.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and Eating Disorders yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all Eating Disorders trials Full LSD profile Full Eating Disorders profile